Business
CRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual Meeting
ZUG, Switzerland and BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating
About this update from Crispr Therapeutics Ag
[{"type":"text","content":"ZUG, Switzerland and BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster on CTX110®, its wholly-owned allogeneic CAR-T cell investigational therapy targeting CD19+ B-cell malignancies, at the American Society of Hematology (ASH) 2022 Annual Meeting, taking place December 10-13, 2022, virtually and at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The ASH abstract includes preliminary data from 32 patients with Large B-Cell Lymphoma (LBCL) who have been dosed in the Company’s ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110®. The poster presentation will include updated results from the CARBON trial. The ASH abstract is now available at www.hematology.org. Title: CTX110 Allogeneic CRISPR-Cas9–Engineered CAR-T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results From the Phase 1 Dose Escalation CARBON StudySession Name: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster IIISession Date: Monday, December 12, 2022Presentation Time: 6:00 PM - 8:00 PM ETAbstract Number: 4629Location: Ernest N. Morial Convention Center, Hall D About CTX110 and CARBON TrialCTX110, a wholly owned program of CRISPR Therapeutics, is a healthy donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19, or CD19. CTX110 is being investigated in the ongoing CARBON trial, a Phase 1 single-arm, multi-center, open label clinical trial, CARBON, is designed to assess the safety and efficacy of several dose levels of CTX110 for the treatment of relapsed or refractory B-cell malignancies. CTX110 has been granted Regenerative Medicine Advanced Therapy designation from the FDA. About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene editing platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopath...